Clinical trial on ibandronate in patients with tumor-associated hypercalcemia / 中华肿瘤杂志

ABSTRACT

<p><b>OBJECTIVE</b>Ibandronate, a third generation bisphosphonate, inhibits bone resorption in human and animal studies. This study is to evaluate the efficacy and safety of ibandronate as a single agent in patients with tumor-associated hypercalcemia.</p><p><b>METHODS</b>An open, multicenter, non-controlled clinical trial was conducted in 22 patients. The patients received 2 mg ibandronate intravenously if the corrected calcium was less than 3.0 mmol/L but more than 2.7 mmol/L; they received 4 mg ibandronate iv if corrected calcium was more than 3.0 mmol/L.</p><p><b>RESULTS</b>There was 100% efficacy in these two dose groups but the calcium correcting effect was more pronounced in the 4-mg dose group than the 2-mg dose group. The most common adverse reactions were fever and skin itching with an incidence of 4.5%.</p><p><b>CONCLUSION</b>Ibandronate is active in patients with tumor-associated hypercalcemia and the adverse effects are well tolerated.</p>